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Context: Polycystic ovary syndrome (PCOS) is the most common cause of anovulation. A key feature
of PCOS is arrest of follicles at the small- to medium-sized antral stage.
Objective and Design: To provide further insight into the mechanism of follicle arrest in PCOS, we
profiled (i) gonadotropin receptors; (ii) characteristics of aberrant steroidogenesis; and (iii) ex-
pression of anti-Mu¨llerian hormone (AMH) and its receptor in granulosa cells (GCs) from unsti-
mulated, human small antral follicles (hSAFs) and from granulosa lutein cells (GLCs).
Setting: GCs from hSAFs were collected at the time of cryopreservation of ovarian tissue for fertility
preservation and GLCs collected during oocyte aspiration before in vitro fertilization/intracytoplasmic
sperm injection.
Participants: We collected hSAF GCs from 31 women (98 follicles): 10 with polycystic ovaries (PCO)
and 21 without. GLCs were collected from 6 women with PCOS and 6 controls undergoing IVF.
Main Outcome Measures: Expression of the following genes: LHCGR, FSHR, AR, INSR, HSD3B2,
CYP11A1, CYP19, STAR, AMH, AMHR2, FST, INHBA, INHBB in GCs andGLCswere compared between
women with PCO and controls.
Results: GCs in hSAFs from women with PCO showed higher expression of LHCGR in a subset (20%) of
follicles. Expressionof FSHR (P,0.05),AR (P,0.05), andCYP11A1 (P,0.05)was lower, andexpressionof
CYP19A1 (P, 0.05), STAR (P, 0.05),HSD3B2 (P5NS), and INHBA (P,0.05)was higher in PCOGCs. Gene
expression inGL cells differedbetweenwomenwithandwithout PCOSbut alsodiffered fromthat inGCs.
Conclusions: Follicle arrest in PCO is characterized in GCs by differential regulation of key genes
involved in follicle growth and function. (J Clin Endocrinol Metab 104: 6182–6192, 2019)
Polycystic ovary syndrome (PCOS) is the most com-mon endocrinopathy in young women, affecting up
to 15% of women of childbearing age (1–4). Despite its
prevalence, the underlying, complex pathophysiology of
PCOS remains poorly understood. However, there is
evidence for disordered ovarian follicular development
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that can be observed even at the early preantral stages (5).
The later, gonadotropin-dependent, stages of follicle
development are characterized by arrest at the small to
medium-sized antral follicle stage and failure to progress
to ovulation (5–7). The exact cause of aberrant follicle
development is unknown, but follicle arrest is associated
with elevated serum concentrations of LH, anti-Mu¨llerian
hormone (AMH), insulin, and androgens and a relative
deficiency of FSH (8). Recent genome-wide association
studies have found susceptibility loci close to genes
encoding FSH receptor (FSHR), FSH B polypeptide gene
(FSHB), and LH choriogonadotropin receptor (LHCGR),
implicating gonadotropins and their receptors in the
pathogenesis of PCOS (9–11).
Inappropriate (premature) responsiveness of gran-
ulosa cells (GCs) to LH may also play a part in follicle
arrest in PCOS. Willis et al. (12, 13) examined GCs from
human small antral follicles (hSAFs) taken from women
with normal ovaries and regular cycles, which showed a
response to FSH (as predicted) but no response to LH in
terms of steroid production. GCs from women with
anovulatory PCOS, however, showed significantly more
variability of responsiveness to LH compared with
ovulatory women [with or without polycystic ovaries
(PCO)], with some follicles behaving as normal ovaries
(i.e., no response to LH), but with a significant subcohort
displaying inappropriate responsiveness to LH. In ad-
dition to inappropriate responsiveness to LH, cultured
GCs from hSAFs in PCOS women also show augmented
estradiol and progesterone production in response to
FSH (12, 13).
The aberrant LH responsiveness of GCs in PCOS is
likely to be due to early acquisition of LHCGR (and/or
their function) in GCs, which may result in terminal
differentiation of GCs and subsequent arrest of follicle
growth. However, Jeppesen et al. (14) detected LHCGR
gene expression in GCs of follicles from healthy persons
as small as 3 mm. Jakimiuk et al. (15) also studied GCs
from women with PCOS and found increased gene ex-
pression of LHCGR and CYP11A1 (catalyzing con-
version of cholesterol to pregnenolone by side-chain
cleavage) in GCs from hSAFs compared with cells from
regularly cycling women. However, that study did not
include quantitative RT-PCR analysis and has not been
replicated, nor has a comprehensive study of expression
of gonadotropin, androgen receptor, and steroidogenic
enzymes been carried out.
Another factor implicated in the mechanism of
arrested follicle growth in PCOS is AMH, a key member
of the TGF-b superfamily of growth factors important
for normal follicle development. Furthermore, re-
searchers recently reported that treatment of pregnant
mice with AMH results in a PCOS-like phenotype in the
offspring, via a mechanism that implies a neuroendocrine
action of AMH (16). Most of circulating AMH is pro-
duced by GCs of large preantral and small antral follicles
(17, 18). AMH inhibits FSH-induced estradiol pro-
duction by GCs in vitro (19) and, because AMH pro-
duction is higher in women with PCOS (20, 21), the
higher ovarian levels of AMH are thought to impair
antral follicle function and contribute to follicle arrest
(22). It has been concluded, on the basis of correlating
serum AMH with antral follicle count on ultrasonog-
raphy, that the production of AMH per follicle is in-
creased in PCOS (23, 24). This view is supported by a
study showing that concentrations of AMH (as measured
by ELISA) were much higher in conditioned media of
cultured GCs from women with PCOS compared with
follicles from controls, although concentrations of AMH
follicular fluid between polycystic and normal ovaries
were not measured (25). Although AMH gene expression
has been measured in luteinized GCs from gonadotropin-
stimulated cycles (and reported to be higher than normal
in women with PCOS) (26) it has not, to our knowl-
edge, been measured in GCs from individual, matched,
unstimulated follicles in women with and without PCO.
Other members of the TGF-b superfamily are plau-
sible candidates for disrupted follicle function in PCOS.
Expression of GDF9 and BMP15 has been found to be
reduced in the oocytes of women with PCOS (27). Fol-
listatin, produced predominantly in GCs (28), inhibits
FSH secretion by binding and neutralizing activin action
(29, 30), and has been shown to be elevated in serum of
women with PCOS (31). Conversely, one study found
that inhibins A and B, which also suppress FSH secretion,
were lower in follicular fluid in large size-matched fol-
licles from women with PCOS (32).
Androgens and insulin may also be important in the
mechanism of follicle arrest in PCOS. Insulin can stim-
ulate GC steroidogenesis and enhance GC responsiveness
to LH (33), and increased androgen synthesis may
augment FSH receptor signaling, both of which may
increase local production of cyclic AMP and encourage
terminal differentiation of GCs (8). However, it is unclear
whether insulin and androgen receptors themselves are
differentially expressed in PCOS GCs.
The principal objective of this study therefore was to
use GCs from small antral follicles to investigate (i) the
expression profile of receptors for the key regulatory
hormones implicated in follicle arrest in PCOS, focusing
on LHCGR and FSHR; (ii) the differences between PCO
and control GCs in gonadotropin-responsive steroido-
genesis in vitro; and (iii) the differential expression of
TGF-b growth factors (particularly AMH) in hSAFs. In
addition, we wished to compare gene expression profiles
in GCs from hSAFs with those in GL cells from large,
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mature, antral follicles, which have frequently been used
as a model of GC function in women with and without
PCOS.
Materials and Methods
Study participants
GCs were collected from hSAFs collected at the time of
cryopreservation of ovarian tissue for fertility preservation. The
follicles were collected randomly and not timed to a particular
point in the menstrual cycle. GCs were collected from 98 follicles
from 31 women: 10 with PCO and 21 with normal ovaries. The
ethical committee of the municipalities of Copenhagen and
Frederiksberg approved the study (journal number; H-2-2011-
044). Polycystic ovaries were defined primarily on the basis of
ovarian volume (.10 mm3). Because these samples were taken
from women with cancer who were about to undergo cancer
treatment, data on menstrual history or hirsutism were not rou-
tinely recorded. However, biochemical indices of PCOS were
measured and are reported in Table 1. Granulosa lutein cells
(GLCs) were collected at the time of oocyte retrieval as part of in
vitro fertilization or oocyte preservation in consenting women.
Samples were collected from six women with PCOS and six
womenwithout. All womenwith PCO in this part of the study had
oligomenorrhea or amenorrhea and therefore fulfilled the
Rotterdam diagnostic criteria for PCOS. Hammersmith and
Queen Charlotte’s Research Ethics Committee, London, United
Kingdom, also approved the study (Reference 08/H0707/152). All
participants provided informed consent.
GC collection and isolation from small antral follicles
The fertility preservation procedure normally involved ex-
cision of one entire ovary. Individual, visible antral follicles
were aspirated with a 23-gauge needle attached to a syringe.
The diameter of the follicles was calculated by using a formula
based on the aspirated volume (18). Follicular fluid was
centrifuged at 1000 rpm for 3 to 5 minutes to isolate GCs.
Larger numbers of peripheral follicles were noted in the PCO
ovaries, and GCs were aspirated from 7 to 14 follicles from
women with PCO compared with 1 to 6 follicles from normal
ovaries. The supernatant was removed, and GCs were washed
in PBS and centrifuged at 1000 rpm for 3 to 5 minutes. The PBS
was discarded, and GCs were snap-frozen in liquid nitrogen.
The samples were collected and stored at the Laboratory of
Reproductive Biology, Rigshospitalet, Denmark.
GLC collection, isolation, and culture
Follicular fluid was aspirated and pooled from follicles of
individual women during the retrieval of oocytes for in vitro
fertilization (IVF)/intracytoplasmic sperm injection. GL cells
were extracted by centrifugation at 1000 rpm for 5 minutes to
separate the fluid from cells, as previously described (34, 35).
The cell pellets were resuspended in M199 (ThermoFisher
Scientific, Waltham, MA) and layered onto a 45% Percoll (GE
Healthcare, Chicago, IL) gradient and then centrifuged at
1600 rpm for 30 minutes to separate red blood cells. The GL
cells at the interface were collected and washed with Dulbecco
PBS (ThermoFisher Scientific). The cells were then cultured at a
density of 13 105 for 4 days in media (DMEMF-12HAMwith
10% FBS, ThermoFisher Scientific) to allow recovery from
potential effects of exogenous hormones (34) and then cultured
in serum-free media for 24 hours before being stored at280°C
or undergoing immediate extraction of RNA.
Quantitative RT-PCR
RNAwas extracted from cells using RNeasy® Plus Mini Kit
(Qiagen Inc., Valencia, CA) according to manufacturer’s in-
structions. The RNA samples were stored at280°C. RNA was
reverse-transcribed into cDNA using the Invitrogen superscript
IV First Strand synthesis system (Invitrogen, Carlsbad, CA).
Quantitative, RT-PCR was carried out on 384 well plates using
POWER SYBR Green (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions on an Applied
Biosystems 7900 HT instrument. Primer sequences are listed
elsewhere (36). Primer efficiency was calculated by using Lin-
Reg software (37); 90% to 110% was considered efficient. A
melt curve was completed to ensure a single product was
formed. The relative mRNA expression of each gene was cal-
culated by using the housekeeping genes b-actin and b2-
microglobulin, which have been validated as stable reference
genes in these cells (38).
Statistical analysis
Statistical analysis was completed by using Prism software,
version 6 (GraphPad Inc,. San Francisco, CA). Unpaired t test
and ANOVA were used to compare means of normally dis-
tributed data (patient data and serum results), and these data
are expressed as mean 6 SEM. Mann-Whitney and Kruskal-
Wallis tests were used to compare the distribution of gene
expression data, which were not normally distributed. These
data are expressed as medians 1 95% CIs. Correlations were
completed by using a Spearman correlation. A P value , 0.05
was considered to indicate a statistically significant difference.
Results
Patient demographic characteristics, clinical
information, and sample details
GCs were collected from unstimulated hSAFs from 31
women undergoing ovarian cryopreservation: 10 with
PCO and 21 with normal ovaries and regular cycles. The
women were aged 16 to 34 years, and the mean age was
similar in women with and those without PCO (Table 1).
Circulating AMH (P 5 0.001), ovarian volume (P ,
0.001), and number of follicles aspirated were higher in
the women with PCO (Table 1). Their underlying cancer
diagnoses are listed in Table 1.
Ninety-eight samples were included: 49 from PCO
women and 49 from controls. The diameter of the hSAFs
from which the GCs were extracted ranged from 2.4 to
12.4 mm, and the mean (6SD) follicle size was 5.9 6
1.4 mm (Fig. 1). The mean was similar for both control
and PCO samples (Fig. 1). The number of follicles included
per woman ranged from 1 to 9 (Fig. 1B). The mean (6SD)
number of follicles included from each woman was 2.56
1.5 from control women and 4.9 6 1.7 from women
with PCO.
GLCs were collected, during oocyte retrieval, from 12
women: 6 with PCOS and 6 without (controls) who were
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undergoing IVF/intracytoplasmic sperm injection or, in
one case, oocyte cryopreservation (Table 2). Women
with PCOS were younger (32 6 1.4 vs 36 6 3.8; P 5
0.056), and received a lower dose of FSH (20756 700 vs
34386 1259; P5 0.06). There were no other differences
between their IVF management protocols.
Gonadotropin, androgen and insulin receptor
expression in GCs and GLCs
LHCGR expression was detectable in all samples.
Median LHCGR expression was 25 times higher in
control GLCs than GCs (P , 0.0001) and was 48 times
higher in PCOS GLCs than in PCO GCs (P , 0.01)
(Fig. 2A). LHCGR was higher in PCOS GLCs than in
control GLCs (P5 0.051) (Fig. 2A). Overall expression of
LHCGRwas low in GCs compared with GLCs. Although
median values of LHCGR in GCs did not significantly
differ between controls and women with PCO, the PCO
group included a subset of follicles (n 5 10; 20% of total
follicles and from 70% of patients with PCOS) in which
relative expression levels were above the normal range
(Fig. 2B). These follicles showed expression levels between
5 and 20 times higher than the median expression of
LHCGR. Expression in these 10 samples (10003 relative
gene expression range, 13- to 52-fold) overlapped with
andwas not significantly different from that of GLCs from
women without PCOS (range, 16- to 205-fold).
Overall, FSHR expression was higher in GCs from
hSAFs than in GL cells, both in women with normal
ovaries (P , 0.01) (Fig. 2C). FSHR gene expression was
lower in GCs from women with PCO than in control
samples (P , 0.01), whereas there was no significant
Figure 1. Number and size of follicles included in the study. (A) Number of follicles per follicle diameter (in millimeters). (B) Number of follicles
included per woman. (C) Distribution of follicle sizes between control and PCO samples. The mean 6 SD follicle size was 5.8 6 1.4 mm for
control samples and 5.9 6 1.5 mm for PCO samples.
Table 1. Patient Clinical Information (GC Samples From hSAFs)
Characteristic Control (n 5 49 Samples) PCO (n 5 49 Samples) P Value
Age, y 25.7 6 5.9 26.6 6 5.5 0.67
Women, n 21 10
Follicles included per woman, n 2.5 6 1.5 4.9 6 1.7 0.0004
Total follicles aspirated per woman (range), n 1–6 7–14
Ovarian volume, mL 7 6 2 14 6 2.8 ,0.0001
Serum LH, IU/L 5.9 6 4.7 9.2 6 6.8 0.10
Serum FSH, IU/L 5.4 6 2.8 5.5 6 2 0.94
Serum AMH, pmol/L 17.8 6 10.8 42 6 24.9 0.001
Serum testosterone, nmol/L 0.5 6 0.49 0.7 6 0.37 0.22
Follicle size, mm 5.8 6 1.4 5.9 6 1.5 0.51
Diagnosis, n
Breast cancer 6 4
Lymphoma 5 1
Brain cancer 4
Medulloblastoma 1
Aplastic anemia 1
Sickle cell anemia 1
Ovarian cancer 1
Colorectal cancer 1 1
Diamond blackfan anemia 1
Sarcoma 4
Values expressed with a plus/minus sign are the mean 6 SD.
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difference between control and PCOS GLCs. Androgen
receptor (AR) expression in control GCs was 3.5 times
higher than in control GLCs (P , 0.05) (Fig. 2D) but
did not differ between PCO GCs and PCOS GLCs. AR
was lower in PCO compared with control GCs (P ,
0.01) (Fig. 2C). Insulin receptor gene (INSR) expres-
sion was similar in GCs and GLCs and between con-
trols and women with PCOS (Fig. 2E). There was no
correlation between LHCGR and AR or FSHR. There
was a strong correlation between AR and FSHR (P 5
0.006) (Fig. 2F). Treatment of GLCs by LH in vitro
significantly reduced expression of AR and FSHR
(Fig. 3).
Steroid enzyme gene expression
Median aromatase (CYP19) gene expression in GCs
was nine times higher in control GLCs than in GCs (P ,
0.0001) and five times lower in PCOS GLCs than in PCO
GCs (P, 0.0001). Median CYP19was twofold higher in
PCOGCs than in controls (P, 0.05) (Fig. 4A).CYP11A1
expression in control GLCs was 15 times higher than in
control GCs (P , 0.01) and 26 times higher in PCOS
GLCs than in PCO GCs (P , 0.0001) (Fig. 4B). Median
CYP11A1 was twofold higher in control GCs compared
with PCOS GCs (P , 0.05). 3-b-hydroxysteroid de-
hydrogenase (HSD3B2) expression in control GLCs was
400 times in higher than in control GLCs (, 0.0001) and
was 300 times higher in PCOS GLCs than in PCO GCs
(P , 0.001) (Fig. 4C). There was a nonsignificant trend
toward higher HSD3B2 in PCO than control GCs (P 5
0.069) and similar in PCOS and control GLCs. Ste-
roidogenic acute regulatory protein (STAR) expression in
control and PCOS GLCs was 194 and 203 times higher
than in control and PCO GCs, respectively (P , 0.0001)
(Fig. 4D). STAR was 2.5-fold higher in PCOS than in
control GCs (P , 0.05). STAR and HSD3B2 were both
positively associated with LHCGR (P , 0.001) (data not
shown).
Growth factor gene expression
Whereas expression levels of AMH, follistatin (FST),
and INHBB were all significantly higher in GCs than
GLCs, they did not differ between PCO and control GCs
(Fig. 5A, 5C, 5E). There was a correlation betweenAMH
and AMHR2 (P , 0.0001) (data not shown). INHBA
but not INHBB expression was higher in PCO GCs than
in control samples (P , 0.05) (Fig. 5D and 5E).
Effect of follicle size on gene expression
To study whether differences between control and
PCO GC samples depended on follicle size, we examined
the impact of follicle size on expression of all genes
studied. The distribution of gene expression in different
follicle sizes did not differ between control and PCO
samples (i.e., over the range of sizes of SAFs from con-
trols or women with PCO, follicle diameter had no
significant effect on gene expression) (39).
Discussion
This is a systematic comparison of gene expression, using
quantitative PCR, in GCs of unstimulated hSAFs be-
tween normal and polycystic ovaries. We examined ex-
pression of key genes involved in follicle growth and
steroidogenesis with a particular emphasis on factors that
we, and others, have previously implicated in the mech-
anism of follicle arrest and anovulation in PCOS (12, 13).
We found evidence of aberrant expression of gonado-
tropin receptors, AR, and steroidogenic enzymes. These
findings were largely confirmed in GCs from preovulatory
follicles obtained in connection with IVF treatment in
women with PCOS and healthy women.
In GCs from unstimulated hSAFs, LHCGR was
expressed at low levels in samples from follicles of all
sizes, from both control and PCO tissue, replicating a
previous study of gene expression in follicles of healthy
women (14). Receptor expression did not correlate with
follicle size over the range of hSAFs used in this study.
There was no overall increase in LHCGR in PCO;
however, a subpopulation of PCO follicles (20%)
expressedLHCGR that was up to 20-fold higher than the
mean expression in GCs from normal ovaries. The lower
level of LHCGR expression (in stark contrast to that of
FSHR) in GCs from hSAFs is consistent with the ob-
servation that, despite low levels of gene expression in
normal follicles, LHCGR is functional only once the
antral follicle has reached a diameter of around 8 to
10 mm (and that in the dominant follicle alone) during
the second half of the follicular phase of a normal cycle.
This is supported by the lack of LH-responsive steroid
production in GCs from healthy women until the follicle
reaches a diameter of about 10mm (12, 40). In a previous
study of GCs in hSAFs obtained from women with
established PCOS, we found that a significant proportion
of GCs in hSAFs showed a (premature) steroidogenic
Table 2. Patient Clinical Information (GLC Samples)
Characteristic Control (n 5 6) PCOS (n 5 6)
P
Value
Age, y 36 6 3.8 32 6 1.4 0.056
Indication for IVF, n Unexplained: 5
Egg freezing: 1
Anovulatory
PCOS
FSH dose, IU 3438 6 1259 2075 6 700 0.06
Maturation trigger hCG hCG
IVF protocol Antagonist: 5
Flare: 1
Antagonist
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response to LH in vitro,which we interpreted as reflecting
aberrant expression of functional LHCGR receptors in
these follicles (12). It was therefore of particular interest
that, in the current study, we showed that expression of
LHCGR was increased in a subpopulation of hSAFs in
women with PCO.
Although we cannot assume changes in gene expres-
sion equates to altered protein expression and function,
LHCGR expression did strongly correlate with that of
both STAR and HSD3B2, which were higher in PCO
GCs, suggesting the expression of LHCGR relates to GC
steroidogenic activity and especially production of pro-
gesterone and 17-OH-progesterone. The augmented
expression of STAR and HSD3B2 in PCO is consistent
with findings in animal model studies; for example, GCs
from antral follicles of sheep that were exposed pre-
natally to androgens also displayed increased expression
of these enzymes (41). StAR is important in delivering
cholesterol to the mitochondria as a substrate for
CYP11A1, the first enzymatic step in steroidogenesis,
but, interestingly, expression of CYP11A1 was signifi-
cantly lower in GCs of PCO follicles. CYP11A1 is the key
enzyme in metabolism of cholesterol to pregnenolone
(and thereafter HSD3B2 catalyzes conversion to pro-
gesterone) but it is not unusual for there to be a dis-
cordance between gene and protein expression and/or
function.
The underlying cause of hyperresponsiveness to LH in
PCOS is not known. Insulin augments not only basal
production of estradiol and progesterone but also LH-
stimulated steroid accumulation in GC cultures (33).
Insulin receptor expression was not increased in PCO
follicles in this study, but insulin induction of LHCGR in
GCs may have a part to play in women with PCOS who
are characteristically hyperinsulinemic. High circulating
LH levels and elevated LH pulse amplitude and fre-
quency are typical biochemical features of PCOS (42);
they may also contribute to follicle premature LH re-
sponsiveness. Why this occurs in some but not all hSAFs
also remains unclear. One previous study in GCs from
hSAFs found a significantly higher expression of
LHCGR in PCOS, and, interestingly, this was a
Figure 2. Gonadotropin, androgen, and insulin receptor expression
(median 1 95% CI). (A) LHCGR was higher in control and PCOS
(GLCs) (n 5 6) than in control and PCO GCs from small antral follicles
(****P , 0.0001, **P , 0.01) (n 5 49, n 5 49). LHCGR was higher
in PCOS GLCs than in controls (P 5 0.051). LHCGR expression did not
significantly differ between PCO and control GCs; however, in the
PCOS group, a subset of samples (20%, 10 of 49) had an expression
between 5 and 20 times higher than the mean expression of LHCGR.
Figure 2. (Continued). (B) Scatter plot of LHCGR in control and PCO
GCs demonstrating individual PCO samples with higher LHCGR. (C)
Median FSHR expression was higher in control and PCO GCs than in
control and PCOS GLCs (***P , 0.001, **P , 0.01). FSHR expression
was lower in PCO GCs than in controls (*P 5 0.03). FSHR expression
was the same in control and PCOS GLC. (D) AR expression was 3.5-
fold lower in control GLCs than in GCs (*P , 0.05). AR in PCO GCs
was half that of control samples (**P , 0.01). AR in PCOS GLCs was
similar to that in control GLCs. (E) INSR expression was the same in
control and PCO GCs and GLCs. (F) AR and FSHR expression were
positively correlated (P 5 0.006, r 5 0.44).
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feature of most follicles analyzed in that study (15). We
also demonstrated a higher LHCGR expression in GCs
from PCO hSAFs and PCOS GLCs, as has been shown
previously (43, 44).
We found a significantly lower expression of FSHR in
GCs from hSAFs in PCO compared with control. FSHR
is critical for FSH-mediated follicle growth and devel-
opment. The opposite might have been expected, as it has
been shown inmouse and primate ovaries that androgens
induce FSHR (45, 46). There is higher production of
estradiol, in response to FSH, by PCOSGCs in vitro (12),
but increased sensitivity to FSH may be possible despite
lower levels of FSHR expression (and this accords with
the finding of increased expression of CYP19 in our
study). In a study of rat ovaries (47) sustained follicle
stimulation by LH decreases FSHR mRNA levels, FSHR
Figure 4. Gene expression of steroid enzymes in control and PCOS GCs and GLC (median 1 95% CI). (A) CYP19 (aromatase) expression is
twofold higher in PCO than control GCs (*P , 0.05). CYP19 expression in GCs was 9 times higher in control GLCs than in GCs (****P ,
0.0001) and 5 times higher in PCOS GLCs than in PCO GCs (****P , 0.0001). (B) Median CYP11A1 was twofold higher in control GCs
compared with PCOS GCs (*P , 0.05) but was not different between control and PCOS GLCs. CYP11A1 expression in control GLCs was 15
times in higher than in GCs (**P , 0.01) and 26 times higher in PCOS GLCs than in PCO GCs (****P , 0.0001). (C) HSD3B2 expression in
control GLCs was 400 times higher than in GLCs (****P , 0.0001) and was 327 times higher in PCOS GLCs than in PCO GCs (***P , 0.001).
There was a non-significant trend toward higher HSD3B2 in PCO than control GCs (P 5 0.07) and HSD3B2 expression was similar in PCOS and
control GLCs. (D) STAR expression in control and PCOS GLCs was 194 and 203 times higher than in control and PCO GCs, respectively
(****P , 0.0001). STAR expression was 2.5-fold higher in PCO GCs compared with controls (*P , 0.05).
Figure 3. Androgen and FSH receptor expression are downregulated in vitro by LH. (A) AR gene expression in GLCs cultured with and without
LH for 24 h (mean 1 SEM). LH reduced AR expression (*P , 0.05) (n 5 8). (B) FSHR expression was reduced in granulosa lutein cells cultured
with LH 10 nM for 24 h (mean 1 SEM) (***P , 0.001).
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signaling and inhibits FSH-induced follicular growth, so
it is possible that inappropriate LHCGR activation in-
hibits FSHR expression. In addition, we showed (Fig. 3B)
that LH treatment in vitro downregulates FSHR; therefore,
reduced FSHR may result from premature LH/LHCGR
activity.
Reduced FSHR expression is also related to the sig-
nificantly lower AR expression in GCs from hSAFs in
PCO. AR expression correlated strongly with FSHR, as
we have shown previously (48, 49), suggesting a close
interrelationship. We and others have shown that an-
drogen treatment in vitro enhances FSHR expression,
although the mechanism is unknown (46). It is unlikely
that AR directly regulates FSHR because an androgen
response element has not been identified on the FSHR
gene promoter.
We have shown that AR expression is under the
control of LH (Fig. 3A). LH treatment in vitro reduces
AR expression. It is possible that the early responsiveness
to LH seen in PCOS, probably as a result of some follicles
expressing aberrantly high LHCGR and LH activity,
inhibits AR expression, which, in turn, reduces FSHR
expression. This combination of enhanced LHCGR ac-
tivity and low AR and FSHR expression may underpin
the follicular arrest seen in PCOS. The action of LH on
ARmay also explainwhy AR falls dramatically inmature
follicles after the LH surge. This pattern of expression
predisposes to terminal differentiation of the GCs or
“premature luteinization.”
It is notable that we found no differences between
PCO and controls in gene expression of AMH or its
receptor. This suggests that the raised circulating AMH,
consistently observed in PCOS, results from a higher
number of antral follicles rather than increased pro-
duction of AMH per follicle. Indeed, Jeppesen et al. (50)
found a highly significant association between GC AMH
mRNA expression and AMH protein level in the cor-
responding follicular fluid in a large number of individual
antral follicles from normal human ovaries. They showed
that AMH correlates with AMHR2, which we also
found. Furthermore, AMHR2 was, likewise, not signif-
icantly different between control and PCO GCs in our
study.
Inhibins A and B are lower in follicular fluid of size-
matched follicles in PCOS (32). Gene expression in GCs
in our study showed the opposite, with higher INHBA in
PCO and no significant difference in INHBB. This dis-
cordance has been seen previously in mature follicles (51)
and may reflect the temporal differences between GC
gene transcription and protein translation and storage in
follicular fluid. Follistatin expression in GCs in this study
was not different between PCO and controls, which
matches the unchanged FST gene expression that we
Figure 5. Gene expression of growth factors in GLC and GCs
(median 1 95% CI). (A) AMH expression did not differ between
PCO and control GCs. AMH was negligible in GLCs (****P ,
0.0001). (B) AMHR2 expression did not differ between PCOS and
control GCs. (C) FST (follistatin) expression did not differ between
PCOS and control GCs and was higher in GCs than GLCs (****P ,
0.0001, ****P , 0.0001). (D) INHBA was higher in PCO GCs
compared with controls (*P , 0.05). (E) INHBB was higher in
control and PCO GCs compared with control and PCOS GLCs
(****P , 0.0001, ****P , 0.0001).
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previously observed (32). The importance of increased
INHBB expression in PCO GCs remains unclear.
This study also highlights GC dynamics and changes in
expression between those from small antral follicles and
large, luteinized follicles. GCs from large luteinized folli-
cles have dramatically higher expression of genes involved
in progesterone synthesis (LHCGR, STAR, HSD3B2,
CYP11A1) and lower expression of genes involved in
growth and estradiol synthesis (FSHR, CYP19A1, AMH,
AMHR2, FST) when compared with GCs from hSAFs.
The major strength of this study is the use of large
numbers of unstimulated hSAFs from ovarian material
that is normally very difficult to obtain. These GCs have
not been exposed to exogenous gonadotropins as part of
an ovarian stimulation process. This is, to our knowl-
edge, the largest and most comprehensive study of GCs
from hSAFs in PCO and provides valuable insight into
the pathogenesis of follicle arrest.
The samples from hSAFs were obtained from women
with clear morphological evidence of polycystic ovaries,
but an obvious limitation of the study is that we could not
determine whether there were clinical features of poly-
cystic ovary syndrome. Nevertheless, the clear differences
we found in gene expression between normal and PCO
GCs remain valid and, if anything, may underestimate
differences between normal follicles and those from
women with PCOS. Other potential limitations of these
data are the relatively small range of follicle size and the
lack of data from follicles .8 mm. However, it is the
follicles that fall within this range that undergo arrest in
women with PCOS and in which we have previously
shown significant differences in gonadotropin respon-
siveness between healthy women and those with PCOS
(12, 13). We found no obvious correlation between gene
expression and follicle size, as has been shown in some
previous studies. However, that is probably because most
of our samples were from follicles between 4 and 7 mm,
whereas previously reported changes with follicle size
were most pronounced in comparison of results in small
vs large antral follicles (48). Finally, in interpreting the
results in GL cells, it is important to consider that
stimulation protocols can differ between women with
PCOS and that exposure to exogenous gonadotropins in
vivo may affect gonadotropin responsiveness in vitro.
However, we have previously shown that culture of GLs
for 4 days before in vitro stimulation allows recovery of
both LHCGR and FSHR responsiveness (34).
In conclusion, GCs from women with PCO display an
altered profile of gene expression compared with women
with regular cycles, with increased LHCGR in a sub-
population of follicles; reduced CYP11A1, FSHR, and
AR; increased STAR and CYP19; and increased INHBB.
There were, however, no differences between PCO and
controls in INHBA, follistatin, AMH, or AMH receptor.
We suggest that these changes (summarized in Fig. 6), in
particular aberrant LHCGR function, but also reduced
FSHR expression, are key factors leading to premature
arrest of antral follicle growth in PCOS. This study
contributes to the growing body of knowledge around
the complex abnormal follicle dynamics in PCOS.
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